首页 > 市场调查报告书 > 医疗设备

体外诊断

全球感染疾病诊断市场（按产品/服务、检测类型、样本类型、疾病类型、技术、临床应用、最终用户和地区划分）- 预测至 2030 年

市场调查报告书

商品编码

1810320

全球感染疾病诊断市场（按产品/服务、检测类型、样本类型、疾病类型、技术、临床应用、最终用户和地区划分）- 预测至 2030 年

Infectious Disease Diagnostics Market by Product & Service, Test Type, Sample, Technology, Disease, End User - Global Forecast to 2030

出版日期: 2025年09月05日 | 出版商:

MarketsandMarkets | 英文 447 Pages | 订单完成后即时交付

价格

简介目录图表

感染疾病诊断市场预计将从 2025 年的 265.8 亿美元成长到 2030 年的 422 亿美元，预测期内的复合年增长率为 9.7%。

调查范围
调查年份	2024-2030
基准年	2024
预测期	2025-2030
对价单位	金额（十亿美元）
部分	按产品/服务、测试类型、样本类型、疾病类型、技术、临床应用、最终用户和地区
目标区域	北美、欧洲、亚太地区、拉丁美洲、中东和非洲

推动市场成长的因素包括对分散式诊断的日益重视，以及对符合《临床改进法案》(CLIA) 豁免的照护现场(PoC) 检测需求的不断增长。这些趋势极大地促进了即时诊断技术的广泛应用。对高效率医疗服务的需求是推动向分散式即时诊断转变的主要动力。将诊断检测转移到即时诊断，使医疗服务提供者能够直接在患者所在地进行诊断，从而最大限度地缩短从样本采集到结果的时间。

根据检测类型，感染疾病诊断市场可细分为实验室检测和即时诊断 (PoC) 检测。预计在预测期内，即时诊断 (PoC) 检测细分市场将以最高的复合年增长率成长。此细分市场的高成长率得益于主要企业透过产品发布和策略收购加大对创新的关注和投资。与传统实验室检测相比，即时诊断 (PoC) 检测具有许多优势，尤其是在临床和医院环境中。即时诊断 (PoC) 侦测的主要优势在于其快速的周转时间，有助于增强诊断决策。此外，由于即时诊断 (PoC) 检测通常只需要少量样本，因此侵入性较小、效率更高。

感染疾病诊断市场细分为免疫诊断、临床微生物学、聚合酵素链锁反应、恒温核酸增幅技术、DNA定序/次世代定序、DNA微阵列和其他技术。 DNA定序/次世代定序市场预计将在预测期内实现最高的复合年增长率。 DNA定序是一个易于使用的平台，可在临床环境中轻鬆实施并快速提供结果。分析遗传物质的能力为个人化医疗、癌症研究和药物研发等应用开闢了新的可能性。此外，定序技术的进步、跨多个领域的应用扩展以及对个人化医疗日益增长的需求预计将成为未来几年支持该细分市场成长的关键因素。

市场按地区细分为北美、欧洲、亚太、拉丁美洲以及中东和非洲。预计亚太地区在预测期内将实现最高成长率。该地区的新兴经济体GDP稳定成长，可支配收入显着增加，预计将推动医疗支出成长和先进诊断技术的普及。其他成长动力包括感染疾病率和盛行率的上升、医疗基础设施的现代化以及先进诊断技术的普及率不断提高，尤其是在农村地区。

本报告研究了全球感染疾病诊断市场，并按产品/服务、测试类型、样本类型、疾病类型、技术、临床应用、最终用户、区域趋势和公司简介进行细分。

介绍
市场动态
定价分析
专利分析
价值链分析
供应链分析
贸易分析
生态系分析
波特五力分析
监管状况
技术分析
2025-2026年主要会议和活动
影响客户业务的趋势/中断
主要相关人员和采购标准
投资金筹措场景
案例研究分析
人工智慧/生成式人工智慧对感染疾病诊断市场的影响
川普关税对感染疾病诊断市场的影响

第六章感染疾病诊断市场（依产品及服务）

介绍
试剂、套件及耗材
装置
软体和服务

第七章感染疾病诊断市场（依测试类型）

介绍
实验室测试
POC 测试

第八章感染疾病诊断市场（依样本类型）

介绍
血液、血清、血浆
尿
其他的

第九章感染疾病诊断市场（依疾病类型）

介绍
肝炎
HIV
院内感染
蚊媒疾病
HPV
披衣菌感染衣原体
淋病
结核
流感
梅毒
其他的

第 10 章感染疾病诊断市场（按技术）

介绍
免疫诊断
临床微生物学
聚合酵素链锁反应
恒温核酸增幅技术
DNA定序与次世代定序
DNA微阵列
其他的

第 11 章感染疾病诊断市场（依临床应用）

介绍
诊断
筛检

第 12 章感染疾病诊断市场（按最终用户）

介绍
诊断实验室
医院和诊所
学术研究机构
其他的

第十三章感染疾病诊断市场（按地区）

介绍
北美洲
- 北美：宏观经济展望
- 美国
- 加拿大
欧洲
- 欧洲：宏观经济展望
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 其他的
亚太地区
- 亚太地区：宏观经济展望
- 中国
- 日本
- 印度
- 其他的
拉丁美洲
- 拉丁美洲：宏观经济展望
- 巴西
- 墨西哥
- 其他的
中东和非洲
- 中东与非洲：宏观经济展望
- 沙乌地阿拉伯王国（KSA）
- 阿拉伯联合大公国（UAE）
- 其他的

第十四章竞争格局

介绍
主要参与企业的策略/优势
2022-2024年收益占有率分析
2024年市场占有率分析
公司估值矩阵：2024 年关键参与企业
公司估值矩阵：Start-Ups/中小企业，2024 年
估值和财务指标
品牌/产品比较
竞争场景

第十五章公司简介

主要参与企业
- F. HOFFMANN-LA ROCHE LTD.
- ABBOTT
- DANAHER CORPORATION
- BIOMERIEUX
- THERMO FISHER SCIENTIFIC INC.
- SIEMENS HEALTHINEERS AG
- HOLOGIC, INC.
- BECTON, DICKINSON AND COMPANY（BD）
- REVVITY, INC.
- QIAGEN NV
- SEEGENE INC.
其他公司
- QUIDELORTHO CORPORATION
- GRIFOLS, SA
- DIASORIN SPA
- BIO-RAD LABORATORIES, INC.
- SYSMEX CORPORATION
- ORASURE TECHNOLOGIES, INC.
- CO-DIAGNOSTICS, INC.
- SD BIOSENSOR, INC.
- BIOSYNEX SA
- TRINITY BIOTECH
- BRUKER（ELITECHGROUP）
- GENETIC SIGNATURES
- EPITOPE DIAGNOSTICS, INC.
- TRIVITRON HEALTHCARE
- MERIL LIFE SCIENCES PVT. LTD.
- INBIOS INTERNATIONAL, INC.
- UNIOGEN OY
- VELA DIAGNOSTICS
- MOLBIO DIAGNOSTICS LIMITED

第十六章附录

简介目录图表

Product Code: MD 3088

The infectious disease diagnostics market is projected to reach USD 42.20 billion by 2030 from USD 26.58 billion in 2025, at a CAGR of 9.7% during the forecast period.

Scope of the Report
Years Considered for the Study	2024-2030
Base Year	2024
Forecast Period	2025-2030
Units Considered	Value (USD billion)
Segments	Product & Service, Type of Testing, Sample Type, Disease Type, Technology, Clinical Application, and End User
Regions covered	North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa

The factors driving the market growth include the increasing emphasis on decentralized diagnostics and the rising demand for CLIA-waived point-of-care (PoC) tests. These trends have significantly contributed to the widespread adoption of PoC technologies. The need for efficient healthcare delivery primarily fuels the shift towards decentralized PoC testing. By relocating diagnostic testing to point-of-care settings, healthcare providers can perform diagnostics directly at the patient's side, minimizing the time between sample collection and results.

Infectious Disease Diagnostics Market - IMG1

By type of testing, the PoC testing segment is expected to grow at the highest CAGR during the forecast period.

By type of testing, the infectious disease diagnostics market is segmented into laboratory and PoC testing. The PoC testing segment is expected to grow at the highest CAGR during the forecast period. The high growth rate of this segment is attributed to the increasing investments from key companies, with a strong emphasis on innovation through product launches & strategic acquisitions. PoC testing offers several advantages over traditional laboratory testing, particularly in clinical & hospital settings. A key benefit of PoC testing is its rapid turnaround time, enabling enhanced diagnostic decisions. Moreover, PoC testing typically requires smaller sample volumes, making it less invasive and efficient.

By technology, the DNA sequencing & next-generation sequencing segment is expected to grow at the highest CAGR during the forecast period.

The infectious disease diagnostics market is segmented into immunodiagnostics, clinical microbiology, polymerase chain reaction, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, DNA microarray, and other technologies. The DNA sequencing & next-generation sequencing segment is projected to register the highest CAGR during the forecast period. DNA sequencing is a user-friendly platform that is easily implemented in clinical settings to deliver rapid results. Its ability to analyze genetic material has expanded its potential across applications, including personalized medicine, cancer research, and drug discovery. Moreover, advancements in sequencing technologies, broadening applications across multiple domains, and the rising demand for personalized medicine are key factors expected to support the growth of this market segment in the coming years.

By region, the Asia Pacific region is projected to grow at the highest CAGR during the forecast period.

The market is segmented by region into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is expected to experience the highest growth rate during the forecast period. Emerging economies in this region are seeing consistent GDP growth and a notable rise in disposable income, which has been attributed to rising healthcare spending and the uptake of advanced diagnostics. Additional growth drivers include the rising incidence & prevalence of infectious diseases, modernization of healthcare infrastructure, and the increasing adoption of advanced diagnostic technologies, particularly in rural areas.

The break-up of the profile of primary participants in the infectious disease diagnostics market:

By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
By Designation: C-level - 27%, D-level - 18%, and Others - 55%
By Region: North America - 51%, Europe - 21%, the Asia Pacific - 18%, Latin America - 6%, and the Middle East & Africa- 4%

The key players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Danaher Corporation (US), bioMerieux (France), Thermo Fisher Scientific Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (US), Revvity, Inc. (US), Hologic, Inc. (US), QIAGEN N.V. (Netherlands), Seegene Inc. (South Korea), QuidelOrtho Corporation (US), Grifols, S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), OraSure Technologies, Inc. (US), Co-Diagnostics, Inc. (US), SD Biosensor, INC. (South Korea), BIOSYNEX SA (France), Trinity Biotech (Ireland), Bruker (US), Genetic Signatures Ltd. (Australia), Epitope Diagnostics, Inc. (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International, Inc. (US), Unijogen Oy (Finland), Vela Diagnostics (Singapore), and Molbio Diagnostics Limited (India).

Research Coverage:

This research report categorizes the infectious disease diagnostics market by product & service (reagents, kits, and consumables, instruments, and software & services), by type of testing (laboratory testing, PoC testing), by disease type (hepatitis, HIV, hospital-acquired infections, mosquito-borne diseases, HPV, Chlamydia trachomatis, Neisseria gonorrhea, tuberculosis, influenza, syphilis, and other infectious diseases), by sample type (blood, serum, and plasma, urine, and other sample types), by technology (immunodiagnostics, polymerase chain reaction, clinical microbiology, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, DNA microarray, and other technologies), by clinical application (diagnostics and screening), by end user (diagnostic laboratories, hospitals & clinics, academic research institutes, and other end users), and region (North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa). The report's scope covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the infectious disease diagnostics market. A thorough analysis of the key industry players has provided insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches and recent infectious disease diagnostics market developments. This report covers the competitive analysis of upcoming startups in the infectious disease diagnostics market ecosystem.

Reasons to Buy this Report:

The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall infectious disease diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

Analysis of key drivers (Rising prevalence of infectious diseases, rising focus on R&D and funding investments for infectious disease diagnostic products, adoption of innovative & advanced technologies for infectious disease diagnosis, gradual shift from centralized laboratories to decentralized POC testing centers), opportunities (high growth potential of emerging economies), restraints (unfavorable reimbursements), and challenges (stringent regulatory guidelines for ivd products, operational barriers and shortage of skilled laboratory technicians) influencing the growth of the infectious disease diagnostics market.
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the infectious disease diagnostics market.
Market Development: Comprehensive information about lucrative markets - the report analyses the infectious disease diagnostics market across varied regions.
Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the infectious disease diagnostics market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Danaher Corporation (US), bioMerieux (France), and Thermo Fisher Scientific Inc. (US), among others, in the infectious disease diagnostics market.

1 INTRODUCTION

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
- 1.3.1 MARKETS COVERED & REGIONAL SCOPE
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
1.4 KEY STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
- 2.2.1 SECONDARY DATA
  - 2.2.1.1 Key secondary sources
  - 2.2.1.2 Key data from secondary sources
- 2.2.2 PRIMARY DATA
  - 2.2.2.1 Primary sources
  - 2.2.2.2 Key data from primary sources
  - 2.2.2.3 Key industry insights
  - 2.2.2.4 Breakdown of primary interviews
2.3 MARKET SIZE ESTIMATION
- 2.3.1 BOTTOM-UP APPROACH
  - 2.3.1.1 Approach 1: Company revenue estimation approach
  - 2.3.1.2 Approach 2: Presentations of companies and primary interviews
  - 2.3.1.3 Growth forecast
  - 2.3.1.4 CAGR projections
- 2.3.2 TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 MARKET SHARE ASSESSMENT
2.6 RESEARCH ASSUMPTIONS
- 2.6.1 PARAMETRIC ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET OVERVIEW
4.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
4.3 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2025 VS. 2030 (USD MILLION)
4.4 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION)
4.5 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2025 VS. 2030 (USD MILLION)
4.6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
4.7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2025 VS. 2030 (USD MILLION)
4.8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
4.9 INFECTIOUS DISEASE DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
  - 5.2.1.1 Rising prevalence of infectious diseases
  - 5.2.1.2 Rising focus on R&D and funding investments for infectious disease diagnostic products
  - 5.2.1.3 Adoption of innovative & advanced technologies for infectious disease diagnosis
  - 5.2.1.4 Gradual shift from centralized laboratories to decentralized PoC testing centers
- 5.2.2 RESTRAINTS
  - 5.2.2.1 Unfavorable reimbursements
- 5.2.3 OPPORTUNITIES
  - 5.2.3.1 High growth potential of emerging economies
- 5.2.4 CHALLENGES
  - 5.2.4.1 Stringent regulatory guidelines for IVD products
  - 5.2.4.2 Operational barriers and shortage of skilled laboratory technicians
5.3 PRICING ANALYSIS
- 5.3.1 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE DIAGNOSTICS PRODUCTS, 2023-2025
- 5.3.2 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE TEST KITS & ASSAYS, BY KEY PLAYER,2023-2025
- 5.3.3 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY REGION, 2023-2025
5.4 PATENT ANALYSIS
- 5.4.1 LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 TRADE ANALYSIS
- 5.7.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS
- 5.7.2 IMPORT DATA (HS CODE 3822)
- 5.7.3 EXPORT DATA (HS CODE 3822)
5.8 ECOSYSTEM ANALYSIS
- 5.8.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
5.9 PORTER'S FIVE FORCES ANALYSIS
- 5.9.1 THREAT OF NEW ENTRANTS
- 5.9.2 THREAT OF SUBSTITUTES
- 5.9.3 BARGAINING POWER OF BUYERS
- 5.9.4 BARGAINING POWER OF SUPPLIERS
- 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 REGULATORY LANDSCAPE
- 5.10.1 REGULATORY FRAMEWORK
  - 5.10.1.1 North America
    - 5.10.1.1.1 US
    - 5.10.1.1.2 Canada
  - 5.10.1.2 Europe
    - 5.10.1.2.1 Germany
    - 5.10.1.2.2 UK
    - 5.10.1.2.3 France
    - 5.10.1.2.4 Italy
  - 5.10.1.3 Asia Pacific
    - 5.10.1.3.1 China
    - 5.10.1.3.2 Japan
    - 5.10.1.3.3 India
  - 5.10.1.4 Latin America
    - 5.10.1.4.1 Brazil
    - 5.10.1.4.2 Mexico
  - 5.10.1.5 Middle East
    - 5.10.1.5.1 Africa
- 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11 TECHNOLOGY ANALYSIS
- 5.11.1 KEY TECHNOLOGIES
  - 5.11.1.1 Immunodiagnostics
- 5.11.2 COMPLEMENTARY TECHNOLOGIES
  - 5.11.2.1 Polymerase Chain Reaction (PCR)
- 5.11.3 ADJACENT TECHNOLOGIES
  - 5.11.3.1 Next-generation Sequencing (NGS)
5.12 KEY CONFERENCES & EVENTS, 2025-2026
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
- 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.14.2 BUYING CRITERIA
5.15 INVESTMENT & FUNDING SCENARIO
5.16 CASE STUDY ANALYSIS
- 5.16.1 CASE STUDY 1: IMPLEMENTING RAPID PCR TESTING TO IMPROVE NOROVIRUS DIAGNOSIS & BED MANAGEMENT
- 5.16.2 CASE STUDY 2: USING MOLECULAR DIAGNOSTICS TO IDENTIFY ATYPICAL RESPIRATORY INFECTIONS
- 5.16.3 CASE STUDY 3: RAPID DIFFERENTIATION OF VIRAL & BACTERIAL INFECTION IN PEDIATRIC PATIENTS
5.17 IMPACT OF AI/GENERATIVE AI ON INFECTIOUS DISEASE DIAGNOSTICS MARKET
- 5.17.1 INTRODUCTION
- 5.17.2 MARKET POTENTIAL OF AI
- 5.17.3 AI-USE CASES
- 5.17.4 IMPLEMENTATION OF AI, BY KEY COMPANY & CASE
- 5.17.5 FUTURE OF AI IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
5.18 TRUMP TARIFF IMPACT ON INFECTIOUS DISEASE DIAGNOSTICS MARKET
- 5.18.1 INTRODUCTION
- 5.18.2 KEY TARIFF RATES
- 5.18.3 PRICE IMPACT ANALYSIS
- 5.18.4 KEY IMPACT ON COUNTRY/REGION
  - 5.18.4.1 North America
  - 5.18.4.2 Europe
  - 5.18.4.3 Asia Pacific
- 5.18.5 IMPACT ON END-USE INDUSTRIES
  - 5.18.5.1 Diagnostic laboratories
  - 5.18.5.2 Hospitals & clinics
  - 5.18.5.3 Academic research institutes

6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

6.1 INTRODUCTION
6.2 REAGENTS, KITS, AND CONSUMABLES
- 6.2.1 RECURRENT PURCHASE TO PROPEL MARKET
6.3 INSTRUMENTS
- 6.3.1 RAPID TECHNOLOGICAL ADVANCEMENTS FOR ADVANCED ACCURACY TO DRIVE MARKET
6.4 SOFTWARE & SERVICES
- 6.4.1 INCREASING FOCUS ON VALUE-ADDED SERVICES TO SUPPORT MARKET GROWTH

7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING

7.1 INTRODUCTION
7.2 LABORATORY TESTING
- 7.2.1 HIGHER SENSITIVITY & SPECIFICITY TO FUEL UPTAKE
7.3 POC TESTING
- 7.3.1 RAPID TURNAROUND TIME AND INCREASING CLIA APPROVALS FOR POC TESTS TO PROPEL MARKET

8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE

8.1 INTRODUCTION
8.2 BLOOD, SERUM, AND PLASMA
- 8.2.1 HIGHER VERSATILITY, ENHANCED CLINICAL EFFICACY, AND IMPROVED REIMBURSEMENT POLICIES TO DRIVE MARKET
8.3 URINE
- 8.3.1 NON-INVASIVE NATURE AND ENHANCED PATIENT CONVENIENCE TO BOOST DEMAND
8.4 OTHER SAMPLE TYPES

9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE

9.1 INTRODUCTION
9.2 HEPATITIS
- 9.2.1 HEPATITIS B
  - 9.2.1.1 Highly contagious infection and requirement for regular monitoring to fuel market
- 9.2.2 HEPATITIS C
  - 9.2.2.1 Rising incidence of chronic HCV and supportive government initiatives to drive market
- 9.2.3 OTHER HEPATITIS DISEASES
9.3 HIV
- 9.3.1 INCREASING PREVALENCE OF AIDS TO BOOST DEMAND
9.4 HOSPITAL-ACQUIRED INFECTIONS
- 9.4.1 RISING BURDEN OF MRSA INFECTIONS TO FUEL MARKET
9.5 MOSQUITO-BORNE DISEASES
- 9.5.1 RISING INCIDENCE OF DENGUE & MALARIA TO PROPEL MARKET
9.6 HPV
- 9.6.1 RAPID TECHNOLOGICAL ADVANCES TO BOOST DEMAND
9.7 CHLAMYDIA TRACHOMATIS
- 9.7.1 INCREASING AWARENESS INITIATIVES TO SUPPORT MARKET UPTAKE
9.8 NEISSERIA GONORRHEA
- 9.8.1 RISING INCIDENCE OF GONORRHEA TO FUEL MARKET
9.9 TUBERCULOSIS
- 9.9.1 INCREASING BURDEN OF TB IN UNDERSERVED AREAS TO DRIVE MARKET
9.10 INFLUENZA
- 9.10.1 INCREASING FOCUS ON RAPID DIAGNOSIS USING POC TESTING METHODS TO FUEL MARKET
9.11 SYPHILIS
- 9.11.1 IMPROVED SCREENING TECHNOLOGIES TO SUPPORT MARKET UPTAKE
9.12 OTHER INFECTIOUS DISEASES

10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY

10.1 INTRODUCTION
10.2 IMMUNODIAGNOSTICS
- 10.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND DEMAND FOR RAPID DIAGNOSTIC KITS TO DRIVE MARKET
10.3 CLINICAL MICROBIOLOGY
- 10.3.1 RAPID TURNAROUND TIME WITH HIGHER SENSITIVITY & RELIABLE RESULTS TO BOOST DEMAND
10.4 POLYMERASE CHAIN REACTION
- 10.4.1 CONVENIENCE & COST-EFFECTIVENESS TO FUEL UPTAKE
10.5 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
- 10.5.1 ENHANCED SUITABILITY FOR POC TESTING WITH LOW-COST FEATURES TO FUEL UPTAKE
10.6 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
- 10.6.1 ADVANCEMENTS IN SEQUENCING TECHNOLOGIES AND RISING FOCUS ON MOLECULAR TARGETED DRUGS TO PROPEL MARKET
10.7 DNA MICROARRAY
- 10.7.1 HIGH INSTRUMENT COSTS TO LIMIT MARKET
10.8 OTHER TECHNOLOGIES

11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION

11.1 INTRODUCTION
11.2 DIAGNOSTICS
- 11.2.1 INCREASING CLINICAL NEED FOR CONFIRMATORY TESTING & TIMELY TREATMENT TO DRIVE MARKET
11.3 SCREENING
- 11.3.1 GROWING IMPORTANCE OF EARLY DISEASE DETECTION TO FUEL MARKET

12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER

12.1 INTRODUCTION
12.2 DIAGNOSTIC LABORATORIES
- 12.2.1 ABILITY TO CATER TO HIGH-END SPECIALTY TESTING TO PROPEL MARKET
12.3 HOSPITALS & CLINICS
- 12.3.1 IMPROVED REIMBURSEMENTS AND CAPABILITY OF PURCHASING ADVANCED EQUIPMENT TO DRIVE MARKET
12.4 ACADEMIC RESEARCH INSTITUTES
- 12.4.1 INCREASING R&D FUNDING INVESTMENTS TO FUEL MARKET
12.5 OTHER END USERS

13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION

13.1 INTRODUCTION
13.2 NORTH AMERICA
- 13.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
- 13.2.2 US
  - 13.2.2.1 High healthcare expenditure to drive market
- 13.2.3 CANADA
  - 13.2.3.1 Supportive government initiatives for infectious disease prevention to fuel market
13.3 EUROPE
- 13.3.1 EUROPE: MACROECONOMIC OUTLOOK
- 13.3.2 GERMANY
  - 13.3.2.1 High adoption of advanced technologies to propel market
- 13.3.3 UK
  - 13.3.3.1 Increasing number of diagnostic centers to fuel uptake
- 13.3.4 FRANCE
  - 13.3.4.1 Rising expenditure on life sciences R&D to drive market
- 13.3.5 ITALY
  - 13.3.5.1 Rising incidence of chronic diseases to boost demand
- 13.3.6 SPAIN
  - 13.3.6.1 High prevalence of HIV and consolidation of diagnostic laboratories to drive market
- 13.3.7 REST OF EUROPE
13.4 ASIA PACIFIC
- 13.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
- 13.4.2 CHINA
  - 13.4.2.1 Increasing burden of hepatitis B virus cases and growing government focus on health surveillance to drive market
- 13.4.3 JAPAN
  - 13.4.3.1 Presence of established healthcare system and universal reimbursement policies to fuel uptake
- 13.4.4 INDIA
  - 13.4.4.1 High prevalence of TB & HIV to propel market
- 13.4.5 REST OF ASIA PACIFIC
13.5 LATIN AMERICA
- 13.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
- 13.5.2 BRAZIL
  - 13.5.2.1 Rising focus on initiating public-private investments for healthcare improvement to fuel uptake
- 13.5.3 MEXICO
  - 13.5.3.1 Improving accessibility & affordability of healthcare services to support market growth
- 13.5.4 REST OF LATIN AMERICA
13.6 MIDDLE EAST & AFRICA
- 13.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
- 13.6.2 KINGDOM OF SAUDI ARABIA (KSA)
  - 13.6.2.1 Integration of digital health systems and improvements in healthcare infrastructure to fuel market
- 13.6.3 UNITED ARAB EMIRATES (UAE)
  - 13.6.3.1 Rising requirement of high-quality healthcare services to support market growth
- 13.6.4 REST OF MIDDLE EAST & AFRICA

14 COMPETITIVE LANDSCAPE

14.1 INTRODUCTION
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 14.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
14.3 REVENUE SHARE ANALYSIS, 2022-2024
14.4 MARKET SHARE ANALYSIS, 2024
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
- 14.5.1 STARS
- 14.5.2 EMERGING LEADERS
- 14.5.3 PERVASIVE PLAYERS
- 14.5.4 PARTICIPANTS
- 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
  - 14.5.5.1 Company footprint
  - 14.5.5.2 Region footprint
  - 14.5.5.3 Product & Service footprint
  - 14.5.5.4 Type of testing footprint
  - 14.5.5.5 Sample type footprint
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
- 14.6.1 PROGRESSIVE COMPANIES
- 14.6.2 RESPONSIVE COMPANIES
- 14.6.3 DYNAMIC COMPANIES
- 14.6.4 STARTING BLOCKS
- 14.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  - 14.6.5.1 Detailed list of key startups/SMEs
  - 14.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
  - 14.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
14.7 COMPANY VALUATION & FINANCIAL METRICS
- 14.7.1 FINANCIAL METRICS
- 14.7.2 COMPANY VALUATION
14.8 BRAND/PRODUCT COMPARISON
- 14.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS
14.9 COMPETITIVE SCENARIO
- 14.9.1 PRODUCT/SERVICES LAUNCHES & APPROVALS
- 14.9.2 DEALS
- 14.9.3 EXPANSIONS

15 COMPANY PROFILES

15.1 KEY PLAYERS
- 15.1.1 F. HOFFMANN-LA ROCHE LTD.
  - 15.1.1.1 Business overview
  - 15.1.1.2 Products/Services offered
  - 15.1.1.3 Recent developments
    - 15.1.1.3.1 Product/Service launches & approvals
    - 15.1.1.3.2 Deals
    - 15.1.1.3.3 Expansions
  - 15.1.1.4 MnM view
    - 15.1.1.4.1 Key strengths
    - 15.1.1.4.2 Strategic choices
    - 15.1.1.4.3 Weaknesses & competitive threats
- 15.1.2 ABBOTT
  - 15.1.2.1 Business overview
  - 15.1.2.2 Products/Services offered
  - 15.1.2.3 Recent developments
    - 15.1.2.3.1 Product/Service launches & approvals
    - 15.1.2.3.2 Deals
  - 15.1.2.4 MnM view
    - 15.1.2.4.1 Key strengths
    - 15.1.2.4.2 Strategic choices
    - 15.1.2.4.3 Weaknesses & competitive threats
- 15.1.3 DANAHER CORPORATION
  - 15.1.3.1 Business overview
  - 15.1.3.2 Products/Services offered
  - 15.1.3.3 Recent developments
    - 15.1.3.3.1 Product/Service launches & approvals
    - 15.1.3.3.2 Deals
    - 15.1.3.3.3 Expansions
  - 15.1.3.4 MnM view
    - 15.1.3.4.1 Key strengths
    - 15.1.3.4.2 Strategic choices
    - 15.1.3.4.3 Weaknesses & competitive threats
- 15.1.4 BIOMERIEUX
  - 15.1.4.1 Business overview
  - 15.1.4.2 Products/Services offered
  - 15.1.4.3 Recent developments
    - 15.1.4.3.1 Product/Service launches & approvals
    - 15.1.4.3.2 Deals
  - 15.1.4.4 MnM view
    - 15.1.4.4.1 Key strengths
    - 15.1.4.4.2 Strategic choices
    - 15.1.4.4.3 Weaknesses & competitive threats
- 15.1.5 THERMO FISHER SCIENTIFIC INC.
  - 15.1.5.1 Business overview
  - 15.1.5.2 Products/Services offered
  - 15.1.5.3 Recent developments
    - 15.1.5.3.1 Product/Service launches & approvals
    - 15.1.5.3.2 Deals
  - 15.1.5.4 MnM view
    - 15.1.5.4.1 Key strengths
    - 15.1.5.4.2 Strategic choices
    - 15.1.5.4.3 Weaknesses & competitive threats
- 15.1.6 SIEMENS HEALTHINEERS AG
  - 15.1.6.1 Business overview
  - 15.1.6.2 Products/Services offered
  - 15.1.6.3 Recent developments
    - 15.1.6.3.1 Product/Service launches & approvals
    - 15.1.6.3.2 Deals
    - 15.1.6.3.3 Expansions
- 15.1.7 HOLOGIC, INC.
  - 15.1.7.1 Business overview
  - 15.1.7.2 Products/Services offered
  - 15.1.7.3 Recent developments
    - 15.1.7.3.1 Product/Service launches & approvals
    - 15.1.7.3.2 Deals
- 15.1.8 BECTON, DICKINSON AND COMPANY (BD)
  - 15.1.8.1 Business overview
  - 15.1.8.2 Products/Services offered
  - 15.1.8.3 Recent developments
    - 15.1.8.3.1 Product/Service launches & approvals
    - 15.1.8.3.2 Deals
    - 15.1.8.3.3 Expansions
- 15.1.9 REVVITY, INC.
  - 15.1.9.1 Business overview
  - 15.1.9.2 Products/Services offered
  - 15.1.9.3 Recent developments
    - 15.1.9.3.1 Product/Service launches & approvals
- 15.1.10 QIAGEN N.V.
  - 15.1.10.1 Business overview
  - 15.1.10.2 Products/Services offered
  - 15.1.10.3 Recent developments
    - 15.1.10.3.1 Product/Service launches & approvals
    - 15.1.10.3.2 Deals
    - 15.1.10.3.3 Expansions
- 15.1.11 SEEGENE INC.
  - 15.1.11.1 Business overview
  - 15.1.11.2 Products/Services offered
  - 15.1.11.3 Recent developments
    - 15.1.11.3.1 Product/Service launches & approvals
    - 15.1.11.3.2 Deals
    - 15.1.11.3.3 Expansions
15.2 OTHER PLAYERS
- 15.2.1 QUIDELORTHO CORPORATION
- 15.2.2 GRIFOLS, S.A.
- 15.2.3 DIASORIN S.P.A
- 15.2.4 BIO-RAD LABORATORIES, INC.
- 15.2.5 SYSMEX CORPORATION
- 15.2.6 ORASURE TECHNOLOGIES, INC.
- 15.2.7 CO-DIAGNOSTICS, INC.
- 15.2.8 SD BIOSENSOR, INC.
- 15.2.9 BIOSYNEX SA
- 15.2.10 TRINITY BIOTECH
- 15.2.11 BRUKER (ELITECHGROUP)
- 15.2.12 GENETIC SIGNATURES
- 15.2.13 EPITOPE DIAGNOSTICS, INC.
- 15.2.14 TRIVITRON HEALTHCARE
- 15.2.15 MERIL LIFE SCIENCES PVT. LTD.
- 15.2.16 INBIOS INTERNATIONAL, INC.
- 15.2.17 UNIOGEN OY
- 15.2.18 VELA DIAGNOSTICS
- 15.2.19 MOLBIO DIAGNOSTICS LIMITED

16 APPENDIX

16.1 DISCUSSION GUIDE
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
16.3 CUSTOMIZATION OPTIONS
16.4 RELATED REPORTS
16.5 AUTHOR DETAILS

简介目录图表

List of Tables

TABLE 1 INFECTIOUS DISEASE DIAGNOSTICS MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2 INFECTIOUS DISEASE DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES
TABLE 3 INFECTIOUS DISEASE DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS
TABLE 4 REGIONAL HIV DATA, 2024
TABLE 5 INDICATIVE SELLING PRICING TREND OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, 2023-2025
TABLE 6 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE TEST KITS & ASSAYS, BY KEY PLAYER, 2023-2025
TABLE 7 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY REGION, 2023-2025
TABLE 8 INFECTIOUS DISEASE DIAGNOSTICS MARKET: LIST OF MAJOR PATENTS
TABLE 9 IMPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020-2024 (USD MILLION)
TABLE 10 EXPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020-2024 (USD MILLION)
TABLE 11 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
TABLE 12 INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
TABLE 13 CLASSIFICATION OF IVD DEVICES IN EUROPE
TABLE 14 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN
TABLE 17 ASIA PACIFIC: LIST OF KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025-DECEMBER 2026
TABLE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (%)
TABLE 22 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY RANK
TABLE 23 IMPLEMENTATION OF AI, BY KEY COMPANY & CASE
TABLE 24 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 25 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)T
TABLE 26 KEY REAGENTS, KITS, AND CONSUMABLES CURRENTLY AVAILABLE
TABLE 27 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY REGION, 2023-2030 (USD MILLION)
TABLE 28 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 29 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 30 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 31 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 33 KEY INSTRUMENTS CURRENTLY AVAILABLE
TABLE 34 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2023-2030 (USD MILLION)
TABLE 35 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 36 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 37 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 38 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 40 KEY SOFTWARE & SERVICES CURRENTLY AVAILABLE
TABLE 41 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2023-2030 (USD MILLION)
TABLE 42 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 43 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 44 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 45 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 47 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 48 KEY LABORATORY TEST TYPES CURRENTLY AVAILABLE
TABLE 49 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY REGION, 2023-2030 (USD MILLION)
TABLE 50 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 51 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 52 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 53 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 55 KEY POC TESTING TYPES CURRENTLY AVAILABLE
TABLE 56 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY REGION, 2023-2030 (USD MILLION)
TABLE 57 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 58 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 59 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 60 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 62 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 63 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY REGION, 2023-2030 (USD MILLION)
TABLE 64 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 65 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 66 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 67 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 68 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 69 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2023-2030 (USD MILLION)
TABLE 70 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 71 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 72 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 73 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 74 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 75 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2023-2030 (USD MILLION)
TABLE 76 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 77 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 78 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 79 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 80 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 81 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 82 KEY HEPATITIS TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 83 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2023-2030 (USD MILLION)
TABLE 84 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 85 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 86 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 87 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 88 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 89 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 90 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY REGION, 2023-2030 (USD MILLION)
TABLE 91 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 92 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 93 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 94 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 95 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 96 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY REGION, 2023-2030 (USD MILLION)
TABLE 97 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 98 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 99 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 100 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 101 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 102 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY REGION, 2023-2030 (USD MILLION)
TABLE 103 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 104 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 105 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 106 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 107 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 108 KEY HIV TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 109 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION, 2023-2030 (USD MILLION)
TABLE 110 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 111 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 112 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 113 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 114 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 115 KEY HAI TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 116 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2023-2030 (USD MILLION)
TABLE 117 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 118 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 119 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 120 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 121 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 122 KEY DENGUE-TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 123 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY REGION, 2023-2030 (USD MILLION)
TABLE 124 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 125 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, 2023-2030 (USD MILLION)
TABLE 126 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 127 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 128 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 129 KEY HPV TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 130 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION, 2023-2030 (USD MILLION)
TABLE 131 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 132 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 133 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 134 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 135 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 136 KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 137 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY REGION, 2023-2030 (USD MILLION)
TABLE 138 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 139 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 140 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 141 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 142 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 143 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY REGION, 2023-2030 (USD MILLION)
TABLE 144 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 145 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 146 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 147 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 148 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 149 KEY TUBERCULOSIS TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 150 GLOBAL NUMBER OF NEWLY DIAGNOSED TUBERCULOSIS (TB) CASES, 2023-2030 (IN MILLIONS)
TABLE 151 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2023-2030 (USD MILLION)
TABLE 152 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 153 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 154 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 155 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 156 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 157 KEY INFLUENZA TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 158 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2023-2030 (USD MILLION)
TABLE 159 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 160 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 161 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 162 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 163 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 164 KEY SYPHILIS TESTING PRODUCTS CURRENTLY AVAILABLE
TABLE 165 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY REGION, 2023-2030 (USD MILLION)
TABLE 166 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 167 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 168 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 169 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 170 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 171 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2023-2030 (USD MILLION)
TABLE 172 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 173 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 174 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 175 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 176 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 177 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 178 KEY IMMUNODIAGNOSTICS-BASED PRODUCTS CURRENTLY AVAILABLE
TABLE 179 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2023-2030 (USD MILLION)
TABLE 180 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 181 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 182 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 183 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 184 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 185 KEY CLINICAL MICROBIOLOGY-BASED PRODUCTS CURRENTLY AVAILABLE
TABLE 186 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY REGION, 2023-2030 (USD MILLION)
TABLE 187 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 188 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 189 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 190 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 191 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 192 KEY POLYMERASE CHAIN REACTION-BASED PRODUCTS CURRENTLY AVAILABLE
TABLE 193 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023-2030 (USD MILLION)
TABLE 194 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 195 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 196 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 197 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 198 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 199 KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY-BASED PRODUCTS CURRENTLY AVAILABLE
TABLE 200 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2023-2030 (USD MILLION)
TABLE 201 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 202 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 203 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 204 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 205 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 206 KEY DNA SEQUENCING & NEXT-GENERATION SEQUENCING-BASED PRODUCTS CURRENTLY AVAILABLE
TABLE 207 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2023-2030 (USD MILLION)
TABLE 208 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 209 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, 2023-2030 (USD MILLION)
TABLE 210 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 211 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 212 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 213 KEY DNA MICROARRAY-BASED PRODUCTS CURRENTLY AVAILABLE
TABLE 214 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2023-2030 (USD MILLION)
TABLE 215 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 216 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 217 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 218 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 219 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 220 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023-2030 (USD MILLION)
TABLE 221 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 222 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 223 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 224 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 225 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 226 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 227 KEY DIAGNOSTICS PRODUCTS CURRENTLY AVAILABLE
TABLE 228 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY REGION, 2023-2030 (USD MILLION)
TABLE 229 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 230 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 231 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 232 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 233 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 234 KEY SCREENING PRODUCTS CURRENTLY AVAILABLE
TABLE 235 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY REGION, 2023-2030 (USD MILLION)
TABLE 236 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 237 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 238 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 239 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 240 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 241 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 242 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023-2030 (USD MILLION)
TABLE 243 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 244 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 245 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 246 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 247 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 248 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023-2030 (USD MILLION)
TABLE 249 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 250 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 251 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 252 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 253 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 254 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
TABLE 255 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 256 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 257 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 258 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 259 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 260 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2023-2030 (USD MILLION)
TABLE 261 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 262 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 263 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 264 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 265 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 266 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 267 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 268 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
TABLE 269 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 270 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 271 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 272 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 273 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 274 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 275 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 276 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 277 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
TABLE 278 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 279 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 280 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 281 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 282 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 283 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 284 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 285 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
TABLE 286 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 287 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 288 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 289 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 290 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 291 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 292 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 293 EUROPE: MACROECONOMIC INDICATORS
TABLE 294 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 295 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
TABLE 296 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 297 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 298 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 299 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 300 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 301 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 302 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 303 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
TABLE 304 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 305 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 306 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 307 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 308 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 309 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 310 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 311 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
TABLE 312 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 313 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 314 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 315 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 316 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 317 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 318 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 319 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
TABLE 320 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 321 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 322 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 323 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 324 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 325 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 326 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 327 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
TABLE 328 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 329 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 330 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 331 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 332 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 333 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 334 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 335 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
TABLE 336 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 337 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 338 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 339 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 340 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 341 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 342 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 343 GDP EXPENDITURE ON HEALTHCARE, BY COUNTRY (%)
TABLE 344 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
TABLE 345 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 346 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 347 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 348 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 349 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 350 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 351 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 352 ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 353 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 354 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
TABLE 355 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 356 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 357 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 358 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 359 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 360 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 361 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 362 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
TABLE 363 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 364 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 365 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 366 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 367 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 368 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 369 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 370 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
TABLE 371 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 372 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 373 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 374 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 375 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 376 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 377 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 378 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
TABLE 379 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 380 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 381 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 382 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 383 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 384 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 385 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 386 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
TABLE 387 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 388 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 389 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 390 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 391 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 392 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 393 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 394 LATIN AMERICA: MACROECONOMIC INDICATORS
TABLE 395 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 396 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
TABLE 397 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 398 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 399 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 400 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 401 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 402 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 403 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 404 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
TABLE 405 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 406 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 407 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 408 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 409 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 410 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 411 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 412 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
TABLE 413 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 414 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 415 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 416 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 417 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 418 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 419 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 420 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
TABLE 421 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 422 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 423 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 424 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 425 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 426 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 427 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 428 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
TABLE 429 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 430 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
TABLE 431 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 432 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 433 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 434 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 435 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 436 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 437 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 438 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
TABLE 439 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 440 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 441 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 442 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 443 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 444 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 445 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 446 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
TABLE 447 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 448 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 449 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 450 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 451 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 452 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 453 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 454 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
TABLE 455 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
TABLE 456 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
TABLE 457 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
TABLE 458 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
TABLE 459 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
TABLE 460 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
TABLE 461 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 462 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET, JANUARY 2021-JUNE 2025
TABLE 463 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DEGREE OF COMPETITION
TABLE 464 INFECTIOUS DISEASE DIAGNOSTICS MARKET: REGION FOOTPRINT
TABLE 465 INFECTIOUS DISEASE DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT
TABLE 466 INFECTIOUS DISEASE DIAGNOSTICS MARKET: TYPE OF TESTING FOOTPRINT
TABLE 467 INFECTIOUS DISEASE DIAGNOSTICS MARKET: SAMPLE TYPE FOOTPRINT
TABLE 468 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 469 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)
TABLE 470 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
TABLE 471 INFECTIOUS DISEASE DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
TABLE 472 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DEALS, JANUARY 2021-JUNE 2025
TABLE 473 INFECTIOUS DISEASE DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021- JUNE 2025
TABLE 474 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
TABLE 475 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
TABLE 476 F. HOFFMANN-LA ROCHE LTD.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
TABLE 477 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021-JUNE 2025
TABLE 478 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2021-JUNE 2025
TABLE 479 ABBOTT: COMPANY OVERVIEW
TABLE 480 ABBOTT: PRODUCTS/SERVICES OFFERED
TABLE 481 ABBOTT: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
TABLE 482 ABBOTT: DEALS, JANUARY 2021-JUNE 2025
TABLE 483 DANAHER CORPORATION: COMPANY OVERVIEW
TABLE 484 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 485 DANAHER CORPORATION: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
TABLE 486 DANAHER CORPORATION: DEALS, JANUARY 2021-JUNE 2025
TABLE 487 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021-JUNE 2025
TABLE 488 BIOMERIEUX: COMPANY OVERVIEW
TABLE 489 BIOMERIEUX: PRODUCTS/SERVICES OFFERED
TABLE 490 BIOMERIEUX: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
TABLE 491 BIOMERIEUX: DEALS, JANUARY 2021- JUNE 2025
TABLE 492 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 493 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
TABLE 494 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
TABLE 495 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-JUNE 2025
TABLE 496 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
TABLE 497 SIEMENS HEALTHINEERS AG: PRODUCTS/SERVICES OFFERED
TABLE 498 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES, JANUARY 2021-JUNE 2025
TABLE 499 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021-JUNE 2025
TABLE 500 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021-JUNE 2025
TABLE 501 HOLOGIC, INC.: COMPANY OVERVIEW
TABLE 502 HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED
TABLE 503 HOLOGIC, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
TABLE 504 HOLOGIC, INC.: DEALS, JANUARY 2021- JUNE 2025
TABLE 505 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
TABLE 506 BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES OFFERED
TABLE 507 BECTON, DICKINSON AND COMPANY: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
TABLE 508 BD: DEALS, JANUARY 2021-JUNE 2025
TABLE 509 BD: EXPANSIONS, JANUARY 2021- JUNE 2025
TABLE 510 REVVITY, INC.: COMPANY OVERVIEW
TABLE 511 REVVITY, INC.: PRODUCTS/SERVICES OFFERED
TABLE 512 REVVITY INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
TABLE 513 QIAGEN N.V.: COMPANY OVERVIEW
TABLE 514 QIAGEN N.V.: PRODUCTS/SERVICES OFFERED
TABLE 515 QIAGEN N.V.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
TABLE 516 QIAGEN N.V.: DEALS, JANUARY 2021-JUNE 2025
TABLE 517 QIAGEN N.V.: EXPANSIONS, JANUARY 2021-JUNE 2025
TABLE 518 SEEGENE INC.: COMPANY OVERVIEW
TABLE 519 SEEGENE INC.: PRODUCTS/SERVICES OFFERED
TABLE 520 SEEGENE INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
TABLE 521 SEEGENE INC.: DEALS, JANUARY 2021- JUNE 2025
TABLE 522 SEEGENE INC.: EXPANSIONS, JANUARY 2021- JUNE 2025
TABLE 523 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
TABLE 524 GRIFOLS, S.A.: COMPANY OVERVIEW
TABLE 525 DIASORIN S.P.A.: COMPANY OVERVIEW
TABLE 526 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
TABLE 527 SYSMEX CORPORATION: COMPANY OVERVIEW
TABLE 528 ORASURE TECHNOLOGIES, INC.: COMPANY OVERVIEW
TABLE 529 CO-DIAGNOSTICS, INC.: COMPANY OVERVIEW
TABLE 530 SD BIOSENSOR, INC.: COMPANY OVERVIEW
TABLE 531 BIOSYNEX SA: COMPANY OVERVIEW
TABLE 532 TRINITY BIOTECH: COMPANY OVERVIEW
TABLE 533 BRUKER (ELITECHGROUP): COMPANY OVERVIEW
TABLE 534 GENETIC SIGNATURES: COMPANY OVERVIEW
TABLE 535 EPITOPE DIAGNOSTICS, INC.: COMPANY OVERVIEW
TABLE 536 TRIVITRON HEALTHCARE: COMPANY OVERVIEW
TABLE 537 MERIL LIFE SCIENCES PVT. LTD.: COMPANY OVERVIEW
TABLE 538 INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW
TABLE 539 UNIOGEN OY: COMPANY OVERVIEW
TABLE 540 VELA DIAGNOSTICS: COMPANY OVERVIEW
TABLE 541 MOLBIO DIAGNOSTICS LIMITED: COMPANY OVERVIEW

List of Figures

FIGURE 1 INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2 INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
FIGURE 3 PRIMARY SOURCES
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
FIGURE 7 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS T
FIGURE 8 INFECTIOUS DISEASE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
FIGURE 9 DATA TRIANGULATION METHODOLOGY
FIGURE 10 INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH ASSUMPTIONS
FIGURE 11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
FIGURE 12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2025 VS. 2030 (USD MILLION)
FIGURE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION)
FIGURE 14 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
FIGURE 15 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2025 VS. 2030 (USD MILLION)
FIGURE 16 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2025 VS. 2030 (USD MILLION)
FIGURE 17 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
FIGURE 18 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2025 VS. 2030 (USD MILLION)
FIGURE 19 RISING FOCUS ON R&D FOR INFECTIOUS DISEASE DIAGNOSTICS TO PROPEL MARKET
FIGURE 20 REAGENTS, KITS, AND CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 21 LABORATORY TESTING SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 22 BLOOD, SERUM, AND PLASMA SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 23 HEPATITIS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 24 IMMUNODIAGNOSTICS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 25 DIAGNOSTICS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 26 DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 27 ASIA PACIFIC REGION TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 28 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 29 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2015-DECEMBER 2024)
FIGURE 30 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASES
FIGURE 31 INFECTIOUS DISEASE DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 32 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
FIGURE 33 INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
FIGURE 34 INFECTIOUS DISEASE DIAGNOSTICS MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
FIGURE 36 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
FIGURE 37 NUMBER OF DEALS & FUNDING ACTIVITIES IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
FIGURE 38 MARKET POTENTIAL OF AI IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
FIGURE 39 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
FIGURE 40 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
FIGURE 41 REVENUE ANALYSIS OF KEY PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET (2022-2024)
FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET (2024)
FIGURE 43 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 44 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPANY FOOTPRINT
FIGURE 45 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 46 EV/EBITDA OF KEY VENDORS
FIGURE 47 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 48 INFECTIOUS DISEASE DIAGNOSTICS MARKET: BRAND COMPARISON FOR INSTRUMENTS
FIGURE 49 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
FIGURE 50 ABBOTT: COMPANY SNAPSHOT (2024)
FIGURE 51 DANAHER CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 52 BIOMERIEUX: COMPANY SNAPSHOT (2024)
FIGURE 53 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
FIGURE 54 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)
FIGURE 55 HOLOGIC, INC.: COMPANY SNAPSHOT (2024)
FIGURE 56 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2024)
FIGURE 57 REVVITY, INC.: COMPANY SNAPSHOT (2024)
FIGURE 58 QIAGEN N.V.: COMPANY SNAPSHOT (2024)
FIGURE 59 SEEGENE INC.: COMPANY SNAPSHOT (2024)

02-2729-4219

+886-2-2729-4219

License/价格

全球感染疾病诊断市场（按产品/服务、检测类型、样本类型、疾病类型、技术、临床应用、最终用户和地区划分）- 预测至 2030 年

Infectious Disease Diagnostics Market by Product & Service, Test Type, Sample, Technology, Disease, End User - Global Forecast to 2030

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章重要考察

第五章 市场概况

第六章感染疾病诊断市场（依产品及服务）

第七章感染疾病诊断市场（依测试类型）

第八章感染疾病诊断市场（依样本类型）

第九章感染疾病诊断市场（依疾病类型）

第 10 章感染疾病诊断市场（按技术）

第 11 章感染疾病诊断市场（依临床应用）

第 12 章感染疾病诊断市场（按最终用户）

第十三章感染疾病诊断市场（按地区）

第十四章竞争格局

第十五章 公司简介

第十六章 附录

The break-up of the profile of primary participants in the infectious disease diagnostics market:

Research Coverage:

Reasons to Buy this Report:

The report provides insights into the following pointers:

TABLE OF CONTENTS

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING

8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE

9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE

10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY

11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION

12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER

13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION

14 COMPETITIVE LANDSCAPE

15 COMPANY PROFILES

16 APPENDIX

List of Tables

List of Figures

第一章引言

第五章市场概况

第十五章公司简介

第十六章附录